Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1995 Nov;102(2):368–372. doi: 10.1111/j.1365-2249.1995.tb03791.x

Characterization and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS).

M B Hill 1, J L Phipps 1, R G Malia 1, M Greaves 1, P Hughes 1
PMCID: PMC1553403  PMID: 7586692

Abstract

Immunoblotting was used to detect antibodies reacting with membrane and cytosol preparations of human umbilical vein endothelial cells (HUVEC), fibroblasts and a T lymphoma line HUT78 in 18 patients with anticardiolipin antibodies (ACA) (14 of whom had had a thrombotic event), 11 patients with a recent myocardial infarction and 17 controls. Multiple membrane-specific antibodies to HUVEC were found in 10 of the patients with ACA (28 bands) and in nine of the patients with thromboses (27 bands) in contrast to only three of the patients with myocardial infarction (four bands) and one control (one band). The most frequently recognized HUVEC membrane epitopes were at 33 kD (four sera), 61-63 kD (five sera) and 76-79 kD (four sera). Although cross-reactivity with fibroblast and/or HUT78 membranes was seen at 33 kD, binding at 61-63 kD and 76-79 kD was specific for endothelial membranes. Although no correlations with the presence and titre of ACA were seen, HUVEC membrane-specific antibodies showed a correlation with venous thrombotic events.

Full text

PDF
368

Images in this article

370Fig. 2
on p.370
370Fig. 3
on p.370

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asherson R. A., Khamashta M. A., Ordi-Ros J., Derksen R. H., Machin S. J., Barquinero J., Outt H. H., Harris E. N., Vilardell-Torres M., Hughes G. R. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989 Nov;68(6):366–374. [PubMed] [Google Scholar]
  2. BOWIE E. J., THOMPSON J. H., Jr, PASCUZZI C. A., OWEN C. A., Jr THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS. J Lab Clin Med. 1963 Sep;62:416–430. [PubMed] [Google Scholar]
  3. Boey M. L., Colaco C. B., Gharavi A. E., Elkon K. B., Loizou S., Hughes G. R. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 1983 Oct 8;287(6398):1021–1023. doi: 10.1136/bmj.287.6398.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boey M. L., Loizou S., Colaco C. B., Matkin J. A., Hughes G. R. Antithrombin III in systemic lupus erythematosus. Clin Exp Rheumatol. 1984 Jan-Mar;2(1):53–56. [PubMed] [Google Scholar]
  5. Cariou R., Tobelem G., Bellucci S., Soria J., Soria C., Maclouf J., Caen J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells--inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost. 1988 Aug 30;60(1):54–58. [PubMed] [Google Scholar]
  6. Carreras L. O., Vermylen J. G. "Lupus" anticoagulant and thrombosis--possible role of inhibition of prostacyclin formation. Thromb Haemost. 1982 Aug 24;48(1):38–40. [PubMed] [Google Scholar]
  7. Cervera R., Khamashta M. A., Font J., Ramírez G., D'Cruz D., Montalbán J., López-Soto A., Asherson R. A., Ingelmo M., Hughes G. R. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity. 1991;11(1):1–6. doi: 10.3109/08916939108994701. [DOI] [PubMed] [Google Scholar]
  8. Cui Y. C., Tai P. C., Gatter K. C., Mason D. Y., Spry C. J. A vascular endothelial cell antigen with restricted distribution in human foetal, adult and malignant tissues. Immunology. 1983 May;49(1):183–189. [PMC free article] [PubMed] [Google Scholar]
  9. Elias M., Eldor A. Thromboembolism in patients with the 'lupus'-type circulating anticoagulant. Arch Intern Med. 1984 Mar;144(3):510–515. [PubMed] [Google Scholar]
  10. Freyssinet J. M., Wiesel M. L., Gauchy J., Boneu B., Cazenave J. P. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity--a mechanism for thrombosis. Thromb Haemost. 1986 Jun 30;55(3):309–313. [PubMed] [Google Scholar]
  11. Glas-Greenwalt P., Kant K. S., Dosekun A., Frazier J., Allen C., Pollak V. E. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis. J Lab Clin Med. 1985 Jan;105(1):99–107. [PubMed] [Google Scholar]
  12. Lindsey N. J., Dawson R. A., Henderson F. I., Greaves M., Hughes P. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome. Br J Rheumatol. 1993 Feb;32(2):123–126. doi: 10.1093/rheumatology/32.2.123. [DOI] [PubMed] [Google Scholar]
  13. Lindsey N. J., Henderson F. I., Malia R., Milford-Ward M. A., Greaves M., Hughes P. Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol. 1994 Jan;33(1):20–26. doi: 10.1093/rheumatology/33.1.20. [DOI] [PubMed] [Google Scholar]
  14. Malia R. G., Greaves M., Rowlands L. M., Lawrence A. C., Hume A., Rowell N. R., Moult J., Holt C. M., Lindsey N., Hughes P. Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Clin Exp Immunol. 1988 Sep;73(3):456–460. [PMC free article] [PubMed] [Google Scholar]
  15. Manoussakis M. N., Tzioufas A. G., Silis M. P., Pange P. J., Goudevenos J., Moutsopoulos H. M. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol. 1987 Sep;69(3):557–565. [PMC free article] [PubMed] [Google Scholar]
  16. Mueh J. R., Herbst K. D., Rapaport S. I. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980 Feb;92(2 Pt 1):156–159. doi: 10.7326/0003-4819-92-2-156. [DOI] [PubMed] [Google Scholar]
  17. Nicholson A. N. Antihistamines and sedation. Lancet. 1983 Jul 23;2(8343):211–212. doi: 10.1016/s0140-6736(83)90185-x. [DOI] [PubMed] [Google Scholar]
  18. Page C., Rose M., Yacoub M., Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol. 1992 Sep;141(3):673–683. [PMC free article] [PubMed] [Google Scholar]
  19. Rosenbaum J., Pottinger B. E., Woo P., Black C. M., Loizou S., Byron M. A., Pearson J. D. Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol. 1988 Jun;72(3):450–456. [PMC free article] [PubMed] [Google Scholar]
  20. Schorer A. E., Wickham N. W., Watson K. V. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol. 1989 Mar;71(3):399–407. doi: 10.1111/j.1365-2141.1989.tb04298.x. [DOI] [PubMed] [Google Scholar]
  21. van der Zee J. M., Siegert C. E., de Vreede T. A., Daha M. R., Breedveld F. C. Characterization of anti-endothelial cell antibodies in systemic lupus erythematosus (SLE). Clin Exp Immunol. 1991 May;84(2):238–244. doi: 10.1111/j.1365-2249.1991.tb08155.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES